Lv6
3190 积分 2023-04-24 加入
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
6天前
已完结
Tirzepatide Once Weekly for the Treatment of Obesity
8天前
已完结
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
8天前
已完结
Challenges and opportunities in NASH drug development
4个月前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
4个月前
已完结
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus
5个月前
已完结
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
5个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
5个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
5个月前
已完结
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
5个月前
已完结
皖公网安备34019202002308
